PLUS1
21.57
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| XOMA Corporation | XOMA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.13 | -0.6% | 21.57 | 20.72 | 22.205 | 21.46 | 21.70 | 17:15:59 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 20.00 | 21.57 | 1.57 | 7.28% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 491 | 26,372 | $ 21.04 | $ 554,917 | 38,354 | 14.03 - 28.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 353 | $ 21.57 | USD |
XOMA Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 237.59M | 11.01M | 9.58M | $ 18.37M | $ -16.59M | -0.44 | -14.32 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
XOMA News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/27/2020 | 14:31 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/27/2020 | 14:31 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/27/2020 | 14:31 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/22/2020 | 16:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/05/2020 | 08:12 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 5/05/2020 | 07:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/05/2020 | 07:30 | GlobeNewswire Inc. | XOMA Reports First Quarter 2020 Financial Results and.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XOMA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.60 | 23.59 | 19.65 | 21.57 | 45,186 | 0.97 | 4.71% |
| 1 Month | 24.23 | 25.93 | 18.98 | 21.33 | 42,830 | -2.66 | -10.98% |
| 3 Months | 18.31 | 27.13 | 14.14 | 20.31 | 48,261 | 3.26 | 17.8% |
| 6 Months | 23.85 | 28.85 | 14.14 | 23.13 | 56,538 | -2.28 | -9.56% |
| 1 Year | 18.67 | 28.85 | 14.03 | 20.80 | 58,655 | 2.90 | 15.53% |
| 3 Years | 6.73 | 37.25 | 6.10 | 20.81 | 100,456 | 14.84 | 220.51% |
| 5 Years | 70.80 | 98.60 | 3.96 | 28.18 | 810,337 | -49.23 | -69.53% |
XOMA Description
| XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics. Its proprietary product candidates are X358, X213, X129, and Gevokizumab. The business operations of the company are functioned through the United States, Europe, and the Asia Pacific. XOMA's primary source of revenue is from license and collaboration arrangements, contract services, and royalties and the majority of the revenue is generated from the United States. |
